Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AstraZeneca
Eisai Inc.
Alliance for Clinical Trials in Oncology
AEterna Zentaris
R-Pharm
INSYS Therapeutics Inc
Case Comprehensive Cancer Center